19° Cloudy

Site search

Open user controls
- Log In Using Your Account
  Log In
  
  Don't have an account? Sign Up Today

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Home
- Contact Us
- Subscribe
News
Sports
Features
Classifieds
Obituaries
Subscribe
E-Edition
Community Choice

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

36.51 +1.71 (+4.91%)

Streaming Delayed Price Updated: 9:45 AM EST, Jan 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 Next >

Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations

January 01, 2026

Via TheNewswire.com

Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations

January 01, 2026

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations

December 31, 2025

Via TheNewswire.com

Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations

December 31, 2025

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Via NewMediaWire

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

December 31, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update

November 04, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call

October 28, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment

October 19, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

October 14, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025

September 22, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

FDA Files Corcept’s New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

September 10, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

July 31, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

July 24, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

July 14, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association’s 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

June 23, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

June 05, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

June 02, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 05, 2025

From Corcept Therapeutics

Via Business Wire

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

April 28, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

April 23, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Diabetes Care Publishes Results From Prevalence Phase Of Corcept’s CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

April 21, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

April 07, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

March 31, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

March 10, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

March 03, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

February 26, 2025

From Corcept Therapeutics

Via Business Wire

Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2024 Financial Results, Provide Corporate Update and Host Conference Call

February 12, 2025

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients With Hypercortisolism

December 30, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism

December 16, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes

December 12, 2024

From Corcept Therapeutics Incorporated

Via Business Wire

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

Home
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard Times

Services

Contact Us
Subscription Services
Promote Your Event
Site Forms
Search

ricentral.com
187 Main Street
Wakefield, RI 02879
Phone: 401-789-9744
Email: news@ricentral.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Log In Using Your Account

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

Press Releases about Corcept Therapeutics Incorporated - Common Stock

Sections

Services